Results 61 to 70 of about 31,793 (243)

Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. [PDF]

, 2020
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to
Boivin-Proulx, L-A, Camm, JA, Deneault-Marchand, A, Fox, KAA, Gobeil, F, Mansour, S, Matteau, A, Potter, BJ   +7 more
core   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Progress in the clinical effects and adverse reactions of ticagrelor

Thrombosis Journal
Background Ticagrelor is a novel receptor antagonist that selectively binds to the P2Y12 receptor, thereby inhibiting adenosine diphosphate (ADP)-mediated platelet aggregation.
Peng Wei, Xiaoqing Wang, Qiang Fu, Bangming Cao   +3 more
doaj   +1 more source

Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75–100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study

Platelets, 2020
Patients treated with ticagrelor and aspirin usually suffer from bleeding events, especially mild bleeding which is one of the main factors reducing patients’ adherence to ticagrelor.
Jiannan Li, Zhaoxue Sheng, Yu Tan, Chen Liu, Peng Zhou, Jinying Zhou, Runzhen Chen, Yi Chen, Li Song, Hanjun Zhao, Hongbing Yan   +10 more
doaj   +1 more source

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Ticagrelor is a P2Y12 receptor inhibitor with superior clinical efficacy compared with clopidogrel. However, it is associated with reduced efficacy when combined with a high‐dose aspirin.
Sukhdeep S. Basra, Tracy Y. Wang, DaJuanicia N. Simon, Karen Chiswell, Salim S. Virani, Mahboob Alam, Vijay Nambi, Ali E. Denktas, Anita Deswal, Biykem Bozkurt, Christie M. Ballantyne, Eric D. Peterson, Hani Jneid   +12 more
doaj   +1 more source

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. [PDF]

, 2019
BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction.
Arnold, Susan E., Bhatt, Deepak L., Jennings, Lisa K., Lee, John S., Mays, Michael C., Pollack, Charles V., Umstead, Bret R., Weitz, Jeffrey I., Xu, Sherry   +8 more
core   +1 more source

The efficacy and safety of the prasugrel, ticagrelor, and clopidogrel dual antiplatelet therapies following an acute coronary syndrome: A systematic review and Bayesian network meta-analysis [PDF]

, 2023
Stan Kutcher, Leah K. Flatman, Rachelle Haber, Nandini Dendukuri, Sonny Dandona, James M. Brophy   +5 more
openalex   +1 more source

Successful Management of Coronary Guidewire Fracture Using Intravascular Ultrasound—Guided Stent Jailing Technique During Retrograde Chronic Total Occlusion Recanalization

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Retrograde recanalization of chronic total occlusion can be challenging for its association with a greater risk of device entrapment and fracture. Aggressive advancement of retrograde guidewire through tortuous collateral may increase the risk of guidewire fracture. Stent jailing technique can sometimes be adopted based on the location, length,
Ang Gao, Guang‐Sheng Cai, Ji‐Hong Zou, Meng‐Yun Xu, Feng Qi, Xiao‐Juan Pan, Hong Qiu   +6 more
wiley   +1 more source

Ticagrelor — a legend of modern cardiology

Российский кардиологический журнал
The article presents the evidence on the basis of which the ticagrelor is used in patients with various forms of coronary artery disease, including both acute and chronic.
S. R. Gilyarevsky
doaj   +1 more source

Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark

The Lancet Regional Health. Europe, 2022
Summary: Background: Ticagrelor was introduced in Denmark in 2011 after randomised data showed its superiority over clopidogrel for patients with acute coronary syndrome (ACS). We assessed the effectiveness and safety of ticagrelor implementation in ACS
Pernille Gro Thrane, Kevin Kris Warnakula Olesen, Morten Würtz, Christine Gyldenkerne, Morten Madsen, Lisette Okkels Jensen, Bent Raungaard, Henrik Toft Sørensen, Troels Thim, Steen Dalby Kristensen, Michael Maeng   +10 more
doaj   +1 more source